Anaptysbio (ANAB) Shareholder's Equity Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.53% |
| Dec 31, 2025 | -47.49% |
| Sep 30, 2025 | -134.87% |
| Jun 30, 2025 | -552.81% |
| Mar 31, 2025 | -28.79% |
| Dec 31, 2024 | -19.56% |
| Sep 30, 2024 | -29.92% |
| Jun 30, 2024 | -93.35% |
| Mar 31, 2024 | -75.00% |
| Dec 31, 2023 | -66.39% |
| Sep 30, 2023 | -56.64% |
| Jun 30, 2023 | -51.22% |
| Mar 31, 2023 | -42.22% |
| Dec 31, 2022 | -26.46% |
| Sep 30, 2022 | -27.63% |
| Jun 30, 2022 | -21.11% |
| Mar 31, 2022 | -13.40% |
| Dec 31, 2021 | -10.16% |
| Sep 30, 2021 | 6.49% |
| Jun 30, 2021 | 1.13% |
| Mar 31, 2021 | -4.65% |
| Dec 31, 2020 | -2.04% |
| Sep 30, 2020 | -14.41% |
| Jun 30, 2020 | -14.94% |
| Mar 31, 2020 | -14.44% |
| Dec 31, 2019 | -16.73% |
| Sep 30, 2019 | -15.77% |
| Jun 30, 2019 | 57.35% |
| Mar 31, 2019 | 58.95% |
| Dec 31, 2018 | 58.13% |
| Sep 30, 2018 | 393.00% |
| Jun 30, 2018 | 161.03% |
| Mar 31, 2018 | 167.47% |
| Dec 31, 2017 | 904.18% |